CAINA TECHNOLOGY CO.(301122)
Search documents
采纳股份:截至2025年10月31日公司登记在册的公司股东数为7857户
Zheng Quan Ri Bao· 2025-11-10 12:41
Core Insights - The company, Cai Na Co., stated on November 10 that as of October 31, 2025, the number of registered shareholders at the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. is 7,857 [2] Summary by Category - **Shareholder Information** - The total number of shareholders registered is 7,857 as of the specified date [2]
康臣药业建议采纳股份奖励计划
Zhi Tong Cai Jing· 2025-11-06 11:48
Core Viewpoint - 康臣药业 (01681) has proposed a share award plan to incentivize and reward individuals contributing to the group's growth and development, with the board's decision made on November 6, 2025 [1] Summary by Relevant Categories - **Company Initiatives** - The board of 康臣药业 has resolved to adopt a share award plan as part of its strategy to motivate participants involved in the company's growth [1]
康臣药业(01681)建议采纳股份奖励计划

智通财经网· 2025-11-06 11:43
Core Viewpoint - 康臣药业 has proposed a share award plan to incentivize and reward individuals contributing to the company's growth and development, with the board's decision made on November 6, 2025 [1] Group 1 - The share award plan aims to motivate participants involved in the company's progress [1]
康臣药业(01681.HK)建议采纳股份奖励计划

Ge Long Hui· 2025-11-06 11:38
Core Viewpoint - 康臣药业 has proposed a share award plan to incentivize and reward individuals contributing to the company's growth and development, pending shareholder approval at a special meeting [1] Summary by Relevant Sections - **Share Award Plan** - The board of 康臣药业 has decided to propose the adoption of a share award plan on November 6, 2025 [1] - This plan aims to incentivize and reward participants involved in the company's growth and development [1] - **Regulatory Compliance** - The proposed share award plan will constitute a new share scheme under Chapter 17 of the Listing Rules [1] - According to Listing Rule 17.02(1)(a), the adoption of the share award plan requires approval from shareholders at a special general meeting [1]
医疗器械板块11月6日跌0.31%,丹娜生物领跌,主力资金净流出6.38亿元
Zheng Xing Xing Ye Ri Bao· 2025-11-06 08:51
Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].
采纳股份:全资子公司取得专利证书
Zheng Quan Ri Bao· 2025-11-05 13:38
Core Viewpoint - The company announced that its wholly-owned subsidiary, Anna Medical (Jiangsu) Co., Ltd., has recently received a patent certificate from the National Intellectual Property Administration [2] Group 1 - The patent certificate is a significant achievement for the company, indicating progress in its innovation and development efforts [2]
11月5日晚间重要公告一览
Xi Niu Cai Jing· 2025-11-05 10:15
Group 1 - Triangle Defense signed a gas turbine project development and framework order agreement with Siemens Energy [1] - The development agreement allows Triangle Defense to qualify for supplying specific items to Siemens Energy, detailing technical prerequisites and standards [1] - Triangle Defense specializes in the research, production, and sales of forged products in aviation, aerospace, and shipping industries [1] Group 2 - Aerospace Hongtu was suspended from military procurement for three years due to alleged violations during a procurement activity [2] - The suspension will last from July 6, 2024, to July 6, 2027, affecting the company's participation in military material procurement [2] - Aerospace Hongtu focuses on satellite operations and data collection [3] Group 3 - Kaili Medical's executives purchased a total of 460,000 shares, investing approximately 13.15 million yuan [4] - The average purchase prices were 28.70 yuan and 28.53 yuan per share [4] - Kaili Medical is engaged in the research, production, and sales of medical diagnostic and treatment equipment [5] Group 4 - Muyuan Foods reported a 22.28% year-on-year decline in sales revenue from live pigs in October, totaling 10.33 billion yuan [6] - The average selling price of live pigs decreased by 32.73% year-on-year to 11.55 yuan per kilogram [6] - Muyuan Foods is involved in pig farming and slaughtering [7] Group 5 - Niuwei Co. plans to acquire 40% of its subsidiary Dongwu Machinery for 139 million yuan, aiming for full ownership [8] - Niuwei Co. specializes in the research, manufacturing, and sales of industrial valves [9] Group 6 - Jinlong Automobile reported a 14.71% year-on-year decline in bus sales in October, with 4,121 units sold [10] - Jinlong Automobile focuses on the production and sales of bus products [10] Group 7 - ST Tianshan reported a 242.54% year-on-year increase in sales revenue from live livestock in October, totaling 13.35 million yuan [11] - The company sold 1,367 head of livestock, marking a significant increase compared to previous periods [11] - ST Tianshan is involved in the breeding and sales of cattle and dairy products [12] Group 8 - Ningbo Port expects a 12.4% year-on-year increase in container throughput in October, reaching 4.56 million TEUs [13] - The total cargo throughput is projected to be 99.6 million tons, a 5.3% increase year-on-year [13] - Ningbo Port engages in port handling and logistics services [13] Group 9 - Amcare Pharma received approval for supplementary drug applications and clinical trials for its products [14] - The company is focused on new drug development and utilizes a MAH model for production [14] Group 10 - Lude Environment plans to change its stock name to "Lude Technology" while keeping its full name and stock code unchanged [15] - The company specializes in waste treatment and resource utilization technologies [15] Group 11 - Hualan Co. plans to increase its stake in the company by investing between 30 million and 60 million yuan [16] - The maximum purchase price is set at 58.08 yuan per share [16] - Hualan Co. focuses on the development and sales of packaging materials for injectable drugs [16] Group 12 - Caina Co. is using 140 million yuan of idle funds to purchase structured deposits from a bank, with expected annual yields between 0.70% and 1.85% [17] - Caina Co. specializes in the research, production, and sales of injection and laboratory consumables [17] Group 13 - Zhenghong Technology reported a 52.80% year-on-year decrease in sales revenue from live pigs in October, totaling 4.32 million yuan [18] - The company sold 400 head of pigs, marking a significant decline compared to previous periods [18] - Zhenghong Technology is involved in feed production and pig farming [18] Group 14 - Caida Securities received approval from the CSRC to issue bonds totaling up to 6 billion yuan [19] - The company is engaged in securities brokerage, investment banking, and asset management [19] Group 15 - Jiayuan Technology signed a copper foil supply framework agreement with CATL, establishing a long-term partnership [20] - The agreement includes collaboration in the supply and production of materials for new battery technologies [20] Group 16 - Haikong Group announced the resignation of its general manager due to personal career planning [21] - The company is involved in automotive passenger transport and related services [21] Group 17 - Beizhi Technology's application to acquire 100% of Suzhou Suike Intelligent Technology has been accepted by the Shanghai Stock Exchange [22] - The company specializes in intelligent logistics systems and equipment [22] Group 18 - Yikang Pharma's subsidiary received approval for clinical trials of a new injection for chronic hepatitis B [23] - The company focuses on the production and sales of raw and formulated pharmaceutical products [23] Group 19 - Hengyuan Coal Power plans to acquire 100% of two coal companies for 440 million yuan [24] - The acquisition includes assuming debts totaling 1.137 billion yuan [24] - Hengyuan Coal Power is involved in coal mining and sales [24] Group 20 - Yangpu Medical announced the cancellation of a production arrangement for a medical device [25] - The company specializes in precision medical and testing services [25] Group 21 - Kailong High-Tech plans to establish a 195 million yuan industry fund focusing on unlisted companies [26] - The company is involved in air pollution control and new energy management systems [26] Group 22 - Yingli Co. received approval for its application to acquire a majority stake in a company [27] - The company specializes in precision electronic components and related manufacturing [27] Group 23 - Tianyi Medical's arterial-venous puncture device received EU MDR certification, valid until January 2028 [28] - The company focuses on medical devices for blood purification and care [28] Group 24 - Chuangyuan Co. appointed a new president, effective until the end of the current board term [29] - The company specializes in the design and production of paper products [29] Group 25 - Shanghai Laishi's new indication for a drug received clinical trial approval [30] - The company focuses on the production and sales of blood products [30] Group 26 - Fengmao Co. plans to issue convertible bonds to raise up to 520 million yuan for expansion and working capital [31] - The company specializes in precision rubber components [31] Group 27 - Yinuo Si's shareholder plans to transfer 3% of the company's shares through an inquiry process [32] - The company provides comprehensive R&D services in the biopharmaceutical sector [32] Group 28 - Phoenix Shipping plans to use up to 50 million yuan of idle funds for cash management [33] - The company is involved in dry bulk shipping and logistics services [33] Group 29 - Xingyuan Zhuomei received a notification to supply magnesium alloy components worth 2.021 billion yuan to a new energy vehicle manufacturer [34] - The project is expected to start mass production in the third quarter of 2026 [34] Group 30 - Landai Technology's subsidiary plans to sell electric drive assembly assets for 110 million yuan [35] - The company specializes in power transmission and display technology [35] Group 31 - Yuexiu Capital plans to distribute a cash dividend of 0.90 yuan per share [36] - The company is involved in asset management and private equity [36] Group 32 - Northeast Securities plans to distribute a cash dividend of 1.00 yuan per share, totaling 234 million yuan [37] - The company focuses on wealth management and investment banking [37] Group 33 - Jinguang Electric won a bid for a project from the State Grid worth 21.7976 million yuan [38] - The company specializes in the research and manufacturing of power distribution equipment [39] Group 34 - Huarong Co. plans to repurchase shares worth between 40 million and 125 million yuan [40] - The company focuses on the production and sales of explosion-proof electrical equipment [40] Group 35 - Baiyang Pharma signed a distribution agreement for a blood product, gaining exclusive rights in specific markets [41] - The company specializes in the development and commercialization of medical innovations [41] Group 36 - Li Qun Co.'s director plans to reduce his stake by up to 71,000 shares due to personal financial needs [42] - The company is involved in retail and logistics services [42] Group 37 - Su Li Co.'s shareholder plans to reduce his stake by up to 0.48% of the company's shares [43] - The company specializes in the production and sales of fine chemical products [43] Group 38 - Shenzhen Ruijie obtained a commitment letter for a stock repurchase loan of up to 15.3 million yuan [44] - The company provides project management and evaluation services [44] Group 39 - Fudan Zhangjiang's shareholder plans to reduce his stake by up to 1% of the company's shares [45] - The company focuses on biopharmaceutical research and development [45] Group 40 - Ningbo Zhongbai's shareholder plans to reduce his stake by up to 1% of the company's shares [46] - The company is involved in retail and wholesale operations [46] Group 41 - Jingyi Co. announced a change in control due to a judicial auction of shares [47] - The company specializes in copper processing and digital carbon services [47] Group 42 - Luoping Zinc Electric's subsidiary obtained a new safety production license for mining operations [48] - The company focuses on hydropower and mining activities [48]
采纳股份(301122) - 关于使用部分闲置自有资金进行现金管理的公告
2025-11-05 08:24
证券代码:301122 证券简称:采纳股份 公告编号:2025-090 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司(以下简称"公司")召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会,分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》,同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营,并有效控制风险 的前提下,使用额度不超过人民币 20,000 万元(含本数)的闲置募集资金(含 超募资金)和额度不超过人民币 80,000 万元(含本数)的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内, 资金可循环滚动使用。 同时,在额度范围内授权公司管理层行使相关投资决策权并签署相关文件, 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 (www.cninfo.com.cn)披露的相关公告。 注:公司与上述受托方无 ...
采纳股份(301122) - 关于全资子公司取得专利证书的公告
2025-11-05 08:24
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司(以下简称"公司")全资子公司安纳医疗(江苏) 有限公司(以下简称"安纳医疗"),于近日收到国家知识产权局颁发的专利证 书,具体情况如下: | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 唾液采集器 | 外观设计 | ZL | 安纳医疗 | 2025年11月 | | | | | 202530112372.2 | | 4 日 | 上述专利为公司自主研发,其所涉及技术均与公司主营业务产品技术相关, 专利权自授权公告之日起生效。 证券代码:301122 证券简称:采纳股份 公告编号:2025-091 采纳科技股份有限公司 关于全资子公司取得专利证书的公告 上述专利的取得和运用,不会对公司短期的经营业绩构成重大影响,但有利 于公司进一步完善知识产权保护体系,形成持续创新机制,保持技术的领先地位, 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 1 / 1 2025 ...
采纳股份涨4.52%,成交额4.39亿元,近3日主力净流入4115.14万
Xin Lang Cai Jing· 2025-11-04 07:45
Core Viewpoint - The company, Canar Medical, has seen a significant increase in stock price and trading volume, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction and laboratory consumables [1][2][3]. Group 1: Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The company's main products include injection syringes (45.17% of revenue), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - Canar Medical began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million, down 85.64% year-on-year [7]. - As of October 20, the number of shareholders decreased by 3.61% to 7,547, while the average circulating shares per person increased by 3.75% to 10,022 shares [7]. - The company has distributed a total of 155 million in dividends since its A-share listing, with 122 million distributed over the past three years [8]. Group 3: Market Dynamics - The stock price of Canar Medical increased by 4.52% on November 4, with a trading volume of 439 million and a turnover rate of 18.27%, bringing the total market capitalization to 3.933 billion [1]. - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [3]. - The average trading cost of the stock is 26.11, with the current price approaching a resistance level of 33.74, indicating potential for upward movement if the resistance is broken [6].